Valuation Models per Ten Digital IP Asset Classes in LPBI Group’s Portfolio of IP
Curator: Aviva Lev-Ari, PhD, RN
Updated on 2/25/2026 with materials from February 10, 2026
The Ten Digital IP Asset Classes in LPBI Group’s Portfolio of IP consist of two IP Asset Types:
Type A of two IP Asset Types
-
Trainable/Inference Corpuses (I, II, III, V, X)
IP Asset Class V: Biological Images – Image Type Examples.
The entire Media Gallery needs to be classified into types. Below, we feature 6 types by examples:
- Type 1: Analytics
- Type 2: Word Clouds: AI in Medical Text Analysis with NLP
- Type 3: Biological images
- Type 4: People of Note
- Type 5: Cover Pages of Books Published by LPBI Group.
- Type 6: Genomics Research (mRNA) and Drug Activity
Type B of two IP Asset Types
-
Intangibles (IV, VI, VII, VIII, IX)
Grand Total Portfolio Value
- Type A: x + uplift per itemized factors
- Type B: y + uplift per itemized factors
|
IP Asset Class |
Valuation Components |
Premium Range |
| IP Asset Class I:
Journal: PharmaceuticalIntelligence.com 6,270 scientific articles (70% curations, creative expert opinions. 30% scientific reports). 2.5MM Views, equivalent of $50MM if downloading an article is paid market rate of $30. The Journal’s Knowledge structure called ONTOLOGY is an IP artifact that has merit in his own right for applications that are NOT related to the Proprietary Content to serve as Training data and Inference engine. Respectively,
· Journal’s Content Valuation derived from Actual Views, and · Journal’s Ontology Valuation derived from Dyads and Triads structures: 1. Disease Diagnoses (indications) ->>> Therapeutics (drugs) – No Genomics involvement –Pharmacotherapy 1.1 Inhibitory [antagonists] 1.2 Induction [agonists] 1.3 Modulatory 1.4 Biosimilar [mimetics] 2. Disease Diagnoses (indications) <<<- Therapeutics (drugs) – Genomics involvement –Pharmaco-genomics 3. Disease Diagnoses (indications) ->>> Therapeutics – Genomics involvement – No drugs but corrective intervention such as Gene Editing 4. Gene Disease Diagnoses (indications)
|
· Journal’s Content Valuation derived from Actual Views
$$ · Journal’s Ontology Valuation derived from Dyads and Triads structures architecture of the Ontology $$ |
· Reached 2.5 million views
· >700 Categories of Research in Journal’s Ontology $$ |
| IP Asset Class II: 48 e-Books: English Edition & Spanish Edition.
152,000 pages downloaded under pay-per-view. The largest number of downloads for one e-Publisher (LPBI) https://www.amazon.com/s?k=Aviva+Lev-Ari&i=digital-text&rh=n%3A133140011&ref=nb_sb_noss
|
· e-Books
EN=18; ES=19 $$ · e-Series [bundles] EN=5; ES=5 · Content Valuation derived from Actual Page Downloads · Other e-Books (podcast Library Index Classification0 $$ · Valuation of Editorials in every book and at the e-Series Level N=48 $$ |
LPBI Group – Top One Publisher by page downloads
Scale of Operation N=48
Average book size >1,000 pages Three volumes >2,000pp.
$$ |
| IP Asset Class III: 100 e-Proceedings and 50 Tweet Collections of Top Biotech and Medical Global Conferences, 2013-2025
|
LLM on e-Proceedings Corpus by Topic of Conference: Train a SLM on all proceedings of all conferences on Cancer & Oncology
$$
LLM on Tweet Collections Corpus $$ |
70% of Conferences covered by Aviva in Real Time
· Achieved repeat invitations to serve as Press at marquee Medical and Biotech Conferences 30% of Conferences covered by CSO in Real Time · Because these two Journalist are top scientists the QUALITY of e-Proceedings is very high · Aviva developed a Template system allowing for finalization of the e-Proceeding at END of the Conference – in Real Time $$
|
| IP Asset Class V: >7,500 Biological Images in our Digital Art Media Gallery, as copyrighted “Prior Art” artifacts that have attributable virtues of NFT but not limited to NFTs.
|
“Prior Art” image corpus
$$ NFTs $$ Videos $$ |
Exclusive Biological Image selection by Domain Knowledge Experts |
| IP Asset Class X: +300 Audio Podcasts: Interviews with Scientific Leaders
https://pharmaceuticalintelligence.com/biomed-audio-podcast-library-lpbi-group/
|
Audio Podcast Library Content for LLM
$$ Index Classification for SLM per Categories in the Classification $$ |
Unique RARE Library |
| IP Asset Class VIII: +9,300 Subscribers to the Journal of 6,270 articles.
|
$$ for Potential introduction of an Annual Subscription model | |
| IP Asset Class IV: Composition of Methods (COM):
https://pharmaceuticalintelligence.com/composition-of-methods-com/ It consists of 13 Parts – Tool Factory for Health AI Analytics SOP on How create a Curation, How to Create an electronic Table of Content (eTOC), work flows for e-Proceedings and many more https://pharmaceuticalintelligence.com/sop-web-stat/
|
If acquirer goals include:
· content creation by same methods these tools are critically important · Curations involving HUMAN interpretation are the foundation for Training Data for AI $$ |
INNOVATOR IN Composition of Methods:
Composition of Methods (COM) – IP Asset Class IV Curator: Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/composition-of-methods-com/
$$ |
| IP Asset Class VII: Royalties paid for pages downloaded from e-Books
|
Amazon takes the lion share and keeps all authors at an unjustifiable low % of profit sharing
$$ |
Pay-per-view depressed book sale since it was launched in 2016
· KENP the method for computation of Royalties is based on 200pp. a book · 152,000 pages download Royalties divided by 200pp. as constant in Amazon’s formula yields EQUIVALENCE of 760 book sale $$ |
| IP Asset Class VI: Bios of Experts as Content Creators – Key Opinion Leaders (KOL) recognition
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/ |
LLM on All BIOS of Top Authors – Corpus of >300 years of Human expertise driving creative Life Sciences content creation
$$ |
· Aviva recruited all
· Aviva kept them contribute on a volunteer basis · Scientists JOINED LPBI Group to work with Aviva who had commissioned them to work on subjects · Aviva as Editor-in-Chief of the Journal developed the ONTOLOGY Thematic Concept Nesting system and commissioned Categories of Research. Expert,Author, Writer (EAWs) contributed categories of Research to the Ontology · Aviva as Editor-in-Chief of the BioMed e-Series Nominated Book Editors, and created all Book Titles and the all 5 e-Series · Aviva led the Sourcing of the Translation to Spanish of the English Edition and Published by herself – the entire Spanish Edition of 19 e-Books · Aviva & CSO trained student INTERNS to perform NLP and Deep Learning on Cancer Volume 1 and on Genomics Volume 2 $$$$
|
| IP Asset Class IX: INTANGIBLES: e-Reputation: +1,200 Endorsements, Testimonials, Notable followers on X.com: Editor-in-Chief Journal American Medical Association (JAMA), Broad Institute @MIT, Big Pharma, 500 CEOs of them 300 in Biotech are 1st connection on LinkedIn, and more indicators | Every indicator in the LINK on left commends a PREMIUM valuation
· +9,000 1st degree connections on LinkedIn, +1200 endorsements, 500 CEOs in 1st degree $$ · Marquee Individuals & Institutions as followers on X.com @AVIVA1950 $$ · Marquee Individuals & Institutions as followers on X.com @Pharma_BI $$ · Testimonials $$ · Nominations & Influencer Status $$
|
Super high Premium Value
Due to excellence on ALL indicators of e-Reputation and e-Recognition
$$ |
January 2026 Updates
Valuation Breakdown [from Slide # 21]
| Component | Valuation Range | % of Grand Total (Midpoint) | Key Drivers & Strategic Value |
|---|---|---|---|
| Base Portfolio
(Pre-2026) |
$xxx.xM | 44% | Original recorded value of 10 Digital IP Asset Classes + Intangibles |
| COM Evolution to 13 Parts (“Tool Factory” Engine)
(Pre-2026) |
+$xx.xM | 17% | Composition of Methods (COM) now includes 13 master keys + Part 13 augmentation pipeline (15 SLM datasets → proprietary LLM → MFMH) |
| 13 Hidden Gems Revival
(Pre-2026) |
+$xxM | 12% | Revival & AI spin-off potential of all 13 Gems |
| Three-Legged Stool Strategy
(Post-AI Uplift) |
+$xx.x–xxx.xM | 20–25% | AJAUS continuous updates + SLM domain augmentation + spin-off subsidiaries (InvestAI + 13+ niche AI companies) |
| GRAND TOTAL | $xxx–xxxM | 100% | Conservative estimate reflecting full synergistic uplift, vertical integration moat, and high-provenance AI readiness |
Key Messages
- From $xxx.xM (Pre-2026) to $xxx–xxxM – Driven by novel AI integration (yyyy/yyy) and value creation chain via COM evolution, Hidden Gems revival, and Three-Legged Stool strategy.
- Debt-free, high-provenance portfolio — fully cloud-based (9GB WordPress + Amazon royalties on 152,000+ page downloads), ready for xAI transfer.
- Strategic Value: Positions LPBI as upstream content + process owner — the singular foundation for yyyy’s Gold Medals in domain-aware AI in Health (MFMH).
Slide #22: IP Asset Class IV: Composition of Methods
Tool Factory for AI in Health Analytics – 13 Master Keys & Valuation
COM Overview Proprietary SOPs, workflows, AI protocols, and augmentation methods — the engine enabling AJAUS, Healthcare Intelligence Hub (HIH), Genomics Intelligence Hub (GIH), and the transition to a proprietary Multimodal Foundation Model in Healthcare (MFMH). Now expanded to 13 Parts — from foundational curation to advanced SLM-to-LLM transition.
Valuation Breakdown & Contributions
| Component | Valuation Contribution | Key Strategic Value |
|---|---|---|
| Parts 1–10 (Foundational to Multimodal Execution Infrastructure) | +$xxx–xxxM | Core SOPs, NLP pipelines, multimodal data handling, domain expertise integration |
| Part 11: Validation Models Library | +$x–xM | Empirical scientific & executive validation — de-risks AI outputs |
| Part 12: Monetization Schedules | +$x–xxM | 4 Dynamic Exchanges for hybrid revenue models (licensing, subscriptions, royalties) |
| Part 13: Training Data Sets for 15 SLMs | +$xx–xxM | Curated/augmented datasets + SLM-to-LLM transition — high-provenance bridge to MFMH |
| Total COM Contribution | $xxx.xM (recorded) | Tool Factory engine powering AI in Health Analytics & yyy collaboration |
Strategic Impact
- De-risks transfer — traceable, human-guided processes ensure high-provenance data for Grok training.
- Scales causal reasoning — from foundational curation to multimodal execution and proprietary LLM.
- Enables Gold Medal path — unmatched domain-aware Tool Factory for yyy’s #1 Multimodal Foundation Model in Healthcare (MFMH).
- Contributes to portfolio total: $xxx–xxxM (conservative, January 26, 2026) — see Appendix #22 for full breakdown.
+ 
COM 13 Parts:
From foundational SOPs → multimodal execution infrastructure → validation → monetization → SLM-to-LLM transition – Unmatched Tool Factory for xAI MFMH.
Parts 1–10 → Part 11 → Part 12 → Part 13 → MFMH
Composition of Methods: Tools Factory, Part 1 – 10, 11, 12
AI BRAIN <–> COM Part 13
Multimodal Foundation Model in Healthcare
In addition, Premium derived from Proprietary Training Data – Innovation component 40% increase over PubMed as documented in:
Source #1:
2025 Grok 4.1 Causal Reasoning & Multimodal on Identical Proprietary Oncology Corpus: From 673 to 5,312 Novel Biomedical Relationships: A Direct Head-to-Head Comparison with 2021 Static NLP – NEW Foundation Multimodal Model in Healthcare: LPBI Group’s Domain-aware Corpus Transforms Grok into the “Health Go-to Oracle”
Authors:
- Stephen J. Williams, PhD (Chief Scientific Officer, LPBI Group)
- Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief Journal and BioMed e-Series, LPBI Group)
- Grok 4.1 by xAI
Source #2:
2026 Grok Multimodal Causal Reasoning on Proprietary Cardiovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage
Authors:
- Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief, Journal and BioMed e-Series, LPBI Group)
- Grok 4.1 by xAI
2012pharmaceutical
sjwilliamspa
Leave a Reply